Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Pillar expands commercial partnership with Illumina

January 2025—Pillar Biosciences announced an expansion of its existing partnership with Illumina in which a broader portfolio of its OncoReveal NGS panels will be offered directly through Illumina. The additional research use only NGS panels include OncoReveal Core LBx, Essential LBx, and Fusion LBx for liquid biopsy tumor profiling and OncoReveal Multicancer RNA Fusion (18-driver gene RNA panel) and Solid Tumor v2 (48-gene DNA panel) for solid tumor profiling, for use on Illumina’s MiSeq and NextSeq 550 systems.

StatLab launches KT brand slides, cover glass

January 2025—StatLab Medical Products has launched a self-manufactured premium slide and cover glass brand. StatLab KT slides are developed, manufactured, and sold within the StatLab group and include a nonadhesive KT1, standard adhesive KT3+, and advanced adhesive KT5+. KT portfolio slides are validated for use on the company’s PiSmart slide printers and can be used in digital pathology. KT Koverglass, made from Schott D 263M glass, offers high refractive indices and uniform dimensions, resulting in true-to-life color representation and superior clarity, the company says.

Thermo Fisher, Mainz Biomed to develop a next-gen CRC screening test

January 2025—Mainz Biomed, a Germany-based molecular genetics diagnostic company specializing in cancer diagnostics, announced a collaborative agreement with Thermo Fisher Scientific, through its subsidiary Life Technologies Corp. The companies will jointly develop and potentially commercialize Mainz Biomed’s next-generation colorectal cancer screening product. The test targets the early detection of colorectal cancer and focuses on precancerous lesions, particularly advanced adenomas.

Study finds Aspyre Lung is a rapid, low-input solution for NSCLC testing

January 2025—Biofidelity announced the publication of data that highlight how Aspyre technology addresses the need for rapid, accessible molecular diagnostics informing actionable genomic variants in cancer (Herlihy SE, et al. Transl Lung Cancer Res. 2024;13[11]:3083–3095). The study demonstrates that Aspyre Lung reagents can be easily set up and run at external laboratories within a few days, producing reliable results even from challenging sample types.

UllCore BSI test gets breakthrough device designation

January 2025—Deepull announced it has received breakthrough device designation from the FDA for its UllCore bloodstream infection test. The test detects 95 percent of pathogens associated with bloodstream infections that may lead to sepsis, as well as select genetic determinants of antimicrobial resistance, and has a turnaround time of one hour. The real-time multiplex PCR system extracts and analyzes total microbial DNA from 8 mL of whole blood.

RightBio Metrics gastric pH indicators

January 2025—RightBio Metrics has announced the availability of its RightSpot Gastric pH Indicators. The FDA-cleared, CLIA-waived product uses pH to confirm gastric acidity for tubes intended to end in the stomach. Other than an x-ray, the primary identifier of a properly placed nasogastric or orogastric tube tip, RightBio says, is a pH reading of 5.5 or less. Each indicator is individually packaged in high-density copolymer foil with proprietary surface treatment to prevent air, light, and humidity from penetrating and can be stored at temperatures between -40°C and 52°C.

QIAstat-Dx instruments, assays get IVDR certification

January 2025—Qiagen announced that its QIAstat-Dx syndromic testing systems and associated assays have received CE marking under the European Union in vitro diagnostic medical devices regulation. The certification includes the QIAstat-Dx analyzer, QIAstat-Dx Rise, and panels for detecting gastrointestinal and respiratory illnesses. The submission for IVDR certification of the QIAstat-Dx meningitis/encephalitis panel is expected in the coming months. The company is transitioning more than 180 products to the IVDR framework.

Microbiologics acquires SensID

January 2025—Microbiologics announced the acquisition of SensID, a manufacturer of reference materials and quality controls for molecular diagnostics, with a focus on oncology and precision medicine. The combination of Microbiologics’ infectious disease diagnostic solutions and SensID’s molecular oncology expertise will ensure they are well positioned to lead in the diagnostic quality control market, according to a Microbiologics press statement.

Verichem Labs total protein, albumin reference materials

January 2025—Verichem Laboratories now offers liquid-stable and ready-to-use total protein and albumin clinical reference materials. The multilevel total protein/albumin standard kit, along with the optional and standalone level F, are prepared with human serum albumin and gamma globulin serum proteins in a saline-based solution. The translucent polyethylene dropper vials contain 15 mL of material at each concentration level. Shelf life is 24 months from the manufacturing date.

Roche gets CE mark for Cobas Mass Spec solution

January 2025—Roche announced it has received CE mark approval for its Cobas Mass Spec solution, including the Cobas i 601 analyzer and Ionify reagent pack of four assays for steroid hormones. The CE mark is the first milestone in the global launch of the Cobas Mass Spec solution, Roche said in a press statement. Following the launch, the company will roll out a menu of more than 60 analytes for testing of steroid hormones, vitamin D metabolites, and immunosuppressant drugs, as well as for therapeutic drug monitoring and drugs of abuse testing.

MARKETPLACE

TRENDING